ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions
Jump to:  View All • a b c d e f g h i j k l m n o [p] q r s t u v w x y z
  • Abstract Number: 1388
    Pain Mechanisms in Psoriatic Arthritis: Differentiating Inflammation Related Pain in Enthesitis Using Ultrasound, in Comparison to Functional MRI
  • Abstract Number: 0906
    Paired Autoantibody Specificities from Serum and Immune Complexes Do Not Fully Explain the Circulating Immune Complex Load in Systemic Lupus Erythematosus: A Study on 530 Patients
  • Abstract Number: 2345
    Paired Kidney Biopsies from the AURORA 2 Study of Voclosporin in Active Lupus Nephritis
  • Abstract Number: 2100
    Paradoxical Antagonistic Association of Visceral and Subcutaneous Adipose Tissue with Circulating C-Reactive Protein in Rheumatoid Arthritis
  • Abstract Number: 0449
    Parsing Pathophysiology of Rheumatoid Arthritis-associated Lymphoproliferative Disorders via Whole RNA Transcriptome Analysis: Multi-center Study in Japan
  • Abstract Number: 1349
    Paternal Effects of Anti-TNFs in Inflammatory Arthritis
  • Abstract Number: 1898
    Patient After Visit Instructions at a University Rheumatology Outpatient Clinic: Do They Make a Difference?
  • Abstract Number: 0506
    Patient and Physician Global Assessment of Psoriatic Arthritis Disease Activity: High Concordance in an ArLAR Multinational Study
  • Abstract Number: PP02
    Patient Centered Care: The Complete Picture
  • Abstract Number: 0344
    Patient Engagement and Adherence to Digital Study Tasks: WEARable Activity Tracker Study Exploring Rheumatoid Arthritis Patients’ Disease Activity Using Patient-Reported Outcome Measures, Clinical Measures, and Biometric Sensor Data (the WEAR Study)
  • Abstract Number: 1219
    Patient Experience of Brain Fog to Inform the Development of a De Novo Patient Reported Outcome (PRO) in Patients with Sjögren’s Disease
  • Abstract Number: 0341
    Patient Perspectives on the Usability of a Rheumatoid Arthritis Patient-reported Outcomes Electronic Health Record-based Dashboard: A Mixed-Methods Study
  • Abstract Number: 2276
    Patient Reported Impact of Lupus on Quality of Life
  • Abstract Number: 1294
    Patient Reported Outcome Measures for Rheumatoid Arthritis Disease Activity: Using Rasch Measurement Theory and Cognitive Interviewing to Achieve More Meaningful Measurement
  • Abstract Number: 0285
    Patient Reported Physical Function, Mental Health, and Treatment Patterns in Dermatomyositis
  • Abstract Number: 0330
    Patient-Reported Experiences and Comorbidities in Patients with IgG4-Related Disease with and Without Pancreatic Involvement
  • Abstract Number: 1630
    Patient-Reported Fatigue Associated with Joint Histopathology in Rheumatoid Arthritis
  • Abstract Number: 2024
    Patient-Reported Outcomes in Patients with Lupus Nephritis: A Post Hoc Analysis of Control Arm Data from Two Completed Phase III Randomized Clinical Trials
  • Abstract Number: 1332
    Patient-Reported Outcomes, Disease Activity and Safety in 798 Patients with RA Treated with Filgotinib: Up to 1-Year Interim Results from a Prospective Observational Study (FILOSOPHY)
  • Abstract Number: 0290
    Patient-reported Quality of Life and Working Status Outcomes in Ambulatory Patients with Idiopathic Inflammatory Myopathy
  • Abstract Number: 0263
    Patient, Disease, and Treatment Factors in Remission of Inflammatory Eye Disease
  • Abstract Number: 1303
    Patient’s and Physician’s Evaluation of Global Assessment of Disease Activity over Follow up and Across Disease Activity Levels in Recent-Onset Rheumatoid Arthritis
  • Abstract Number: 0468
    Patients with Autoimmune Skin Diseases Are at Increased Risk of Adverse Pregnancy Outcomes
  • Abstract Number: 1166
    Patients with COVID-19 and Polymyositis Inpatient Outcomes and Hospital Cost: Nationwide Inpatient Sample 2020
  • Abstract Number: 0436
    Patients with Difficult-to-treat Rheumatoid Arthritis Have Higher Levels of Inflammation on Ultrasound
  • Abstract Number: 2277
    Patients with Systemic Lupus Erythematosus: A Comparative Study Between Two Large, Multi-centric, Spanish and Argentinian Registers, Focused on Outcomes Differences
  • Abstract Number: 1026
    Patients’ Barriers to Total Joint Arthroplasty: Associations with the Orthopedic Consultation
  • Abstract Number: 1030
    Patterns in the Prescription, the Denials of Coverage, and the Delays in Dispensation of Janus Kinase Inhibitors
  • Abstract Number: 2145
    Patterns of Use, Effectiveness, Persistence and Cardiovascular Risk in Patients with Rheumatic Diseases Treated with Upadacitinib in a Real-world Setting. UPAREAL Study
  • Abstract Number: 0220
    Paxlovid (Nirmatrelvir Plus Ritonavir) in Patients with Underlying Rheumatological Diseases, in Preventing COVID-19 Related Hospitalization and Death
  • Abstract Number: 0073
    PD-1hi Cells Are Highly Present in the Rheumatoid Joint, and Express Regulatory Capacities
  • Abstract Number: 1707
    PD1-Expressing Regulatory T Cells Found in Inflamed Joints Suppress Tph Cell-B Cell Interactions
  • Abstract Number: 2056
    Pediatric Acute-onset Neuropsychiatric Syndrome: Markers of Inflammation/autoimmunity at Clinical Presentation and Eventual Development of Arthritis and Other Autoimmune Diseases
  • Abstract Number: PP16
    Peer Health Coaches Help Scleroderma Patients Cope with Isolation
  • Abstract Number: 1964
    Penn State Registry of Inflammatory Myopathies (PRIMO) Provides Insights into Disease Features and Co-Morbidity Screening Utilization
  • Abstract Number: 0867
    Pentosan Polysulfate Sodium, a Glycosaminoglycan Mimetic Demonstrates Durable Effects on Pain, Function and Joint Structure in Canine Naturally Occurring Osteoarthritis
  • Abstract Number: 1803
    Perceived Dignity in Patients with Rheumatic Diseases: An Unrecognized Source of Emotional Distress
  • Abstract Number: 2064
    Perceptions of Rheumatology Fellows on Mentorship Quality After Implementation of a Formalized Mentorship Program
  • Abstract Number: 1872
    Performance Analysis of a Deep Learning Algorithm to Detect Positive SIJ MRI According to the ASAS Definition in axSpA Patients
  • Abstract Number: 0096
    Performance Assessment of Lupus Anticoagulant Tests Using Taipan and Ecarin Snake Venom Clotting Times: An International Study from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Core Laboratories
  • Abstract Number: 0581
    Performance Characteristics of a Novel, Fully Automated Multiplexed Immunoassay Microarray Prototype for the Serological Detection of Eleven IgG Autoantibodies Commonly Found in Connective Tissue Diseases
  • Abstract Number: 0580
    Performance of Conventional Cardiovascular Risk Scores in Identifying Subclinical Atherosclerosis in Systemic Lupus Erythematosus
  • Abstract Number: 1880
    Performance of Machine Learning Algorithms in Discriminating Spondyloarthritis Features on Magnetic Resonance Imaging: A Systematic Review and Meta-analysis
  • Abstract Number: 0848
    Performance of Serum MRP8/14, sCD14, IL-6 and Neutrophil CD64 in Isolation and in Combination for Differentiating Flare from Bacterial Infection in Febrile SLE Patients
  • Abstract Number: 1515
    Performance of the Revised CRISS in a Phase 3 Trial of Early Systemic Sclerosis
  • Abstract Number: 2126
    Performance of the Rheumatoid Arthritis Impact of Disease (RAID) Score in Relation to Flares in Disease Activity
  • Abstract Number: 1867
    Peripheral Volumetric Bone Mineral Density and Erosive Disease in Patients with Established Rheumatoid Arthritis: A Cross-Sectional Study Using High-Resolution Peripheral Quantitative Computed Tomography
  • Abstract Number: 0850
    Persistence of Urinary Biomarkers of Intrarenal Inflammation Precedes Loss of Kidney Function in Lupus Nephritis
  • Abstract Number: 2240
    Persistence to Therapy Among Patients with Psoriatic Arthritis Treated with IL-17A or TNFα Inhibitors (IL-17Ai or TNFi)
  • Abstract Number: 1765
    Persistent Cigarette Smoking Is Associated with Rheumatoid Arthritis Onset and Neutrophil Activation in a Prospective Study of At-risk First-Degree Relatives
  • Abstract Number: 0404
    Persistent Pain and Its Predictors After Start of Anti-TNF Therapy in Rheumatoid Arthritis – Is Line of Treatment Linked to Different Pain Patterns?
  • Abstract Number: 0109
    Persistent Prothrombotic Activation of Platelet Pannexin 1 Channels in Antiphospholipid Syndrome
  • Abstract Number: 0929
    Persistent Up- or Down-regulation of SOCS1 Exacerbates the Pathogenesis of Systemic Lupus Erythematosus Through Several Mechanisms
  • Abstract Number: 2302
    Persistently Active Disease in Adult Patients with Childhood Onset Systemic Lupus Erythematosus
  • Abstract Number: 0744
    Personalizing Cardiovascular Risk Prediction for Patients with Systemic Lupus Erythematosus
  • Abstract Number: 1629
    Persons with Rheumatoid Arthritis and Long COVID Had Worse Pre-COVID RA Symptoms and Worse Non-RA Symptoms, as Well as Higher Rates of Fibromyalgia Compared with COVID Infected Long COVID Negative
  • Abstract Number: 1507
    Pharmacodynamic Changes in SLE Relevant Gene Expression Induced by Deucravacitinib in Patients Enrolled in the Phase 2 PAISLEY Trial
  • Abstract Number: 2144
    Pharmacodynamic Effects of Nipocalimab in Patients with Moderate to Severe Active Rheumatoid Arthritis (RA): Results from the Multicenter, Randomized, Double-blinded, Placebo-controlled Phase 2A IRIS-RA Study
  • Abstract Number: 2161
    Pharmacokinetic and Safety Similarity of High- and Low-Concentration Formulations of Adalimumab Biosimilar ABP 501
  • Abstract Number: 1247
    Pharmacokinetic, Pharmacodynamic, and Safety Profile of Subcutaneous Belimumab in Pediatric Patients with Systemic Lupus Erythematosus: Analysis of Data from a Multicenter, Open-Label Trial
  • Abstract Number: 1110
    Pharmacokinetics and Pharmacodynamics of AR882 Following 12-Week Treatment in Patients with Gout
  • Abstract Number: 0535
    Pharmacologic Treatment of Ankylosing Spondylitis in a Large Urban Medical Center: Effects of Socioeconomic Status, Race/Ethnicity and Sex
  • Abstract Number: 0080
    Pharmacological Inhibition of PRMT5 Demonstrates Broad Efficacy in Multiple Preclinical Models of Autoimmunity and Inflammation by Suppressing Th1, Th17 and TNF-Mediated Inflammatory Responses
  • Abstract Number: 1595
    Pharmacological Modulation of Krüppel-like Factor 4 Reduces the Severity of Experimental Osteoarthritis via Tissue Protection and Regeneration
  • Abstract Number: 2487
    Phase 2 Safety and Efficacy of Subcutaneous (s.c.) Dose Ianalumab (VAY736; Anti-BAFFR mAb) Administered Monthly over 28 Weeks in Patients with Systemic Lupus Erythematosus (SLE) of Moderate-to-Severe Activity
  • Abstract Number: 1514
    Phase I Study to Evaluate the Safety of Allogeneic Bone Marrow Derived Mesenchymal Stem Cells for Interstitial Lung Disease in Patients with Connective Tissue Disorders
  • Abstract Number: 0863
    Phenotype and Energy Metabolism Differ Between Osteoarthritic Chondrocytes from Male Compared to Female Patients
  • Abstract Number: 2043
    Phenotype of Musculoskeletal Manifestations in a Canadian Inception Cohort of Pediatric Patients with Inflammatory Bowel Disease
  • Abstract Number: 0260
    Phenotypes of the Patients with More Than One Autoinflammatory Gene Variant: Classified Diseases and Mixed Autoinflammatory Disorders (MAID)
  • Abstract Number: 0284
    Phenotyping Calcinosis: A Rare Manifestation of Rare Diseases
  • Abstract Number: 2112
    Physical Activity in a Cohort of Patients with Rheumatoid Arthritis
  • Abstract Number: 0620
    Physical and Mental Health in Early Systemic Sclerosis: Baseline Results for Patient-Reported Outcomes Measurement Information System-29 from the Collaborative National Quality and Efficacy Registry
  • Abstract Number: 0118
    Physical Performance Among Individuals with Systemic Lupus Erythematosus in a Diverse Population-Based Cohort
  • Abstract Number: 1252
    Physician Global Assessment of Disease Activity in Childhood-Onset Systemic Lupus Erythematosus – Does the Approach Matter?
  • Abstract Number: 1134
    Pilot Study Investigating Adenosine Deaminase-2 as a Disease Activity Biomarker for Cardiac Sarcoidosis
  • Abstract Number: 2076
    Piloting a Rheumatology and Sports Medicine Case-Based Collaborative Learning Curriculum for Medical Students
  • Abstract Number: 1804
    Plant-based Diet Quality and the Risk of Gout: Results from Two Prospective Cohort Studies of US Men and Women
  • Abstract Number: 2371
    Plasma and Urine Cytokine Profiles in Active ANCA-Associated Vasculitis
  • Abstract Number: 0770
    Plasma Matrix Metalloproteinases in Rheumatoid Arthritis-Interstitial Lung Disease: Associations with Disease Presence, Severity, and Subtypes
  • Abstract Number: 1363
    Plasma Neutrophil Extracellular Trap Remnant Levels Are Lower in Premenopausal Healthy Women Using Oral Contraceptive Pills
  • Abstract Number: 1608
    Plasma Proteomic Profiling in Antiphospholipid Antibody-positive Patients with Different Clinical Phenotypes: Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Registry
  • Abstract Number: 1733
    Platelet-Derived Growth Factor Is a Mediator of Disease in an Animal Model of Rheumatoid-Associated Interstitial Lung Disease
  • Abstract Number: 0114
    Platelets Are Highly Activated and Could Participate in Immune Abnormality of APS
  • Abstract Number: 0208
    Pneumocystis Jirovecii Pneumonia (PJP) Prophylaxis (PPX), Investigating the Practice Patterns of Providers for Patients on Chronic, High-Dose Immunosuppression in a Rural Integrated Health System
  • Abstract Number: 0295
    Pneumocystis Jirovecii Pneumonia in Patients with Inflammatory Myopathies
  • Abstract Number: 2160
    Poly-Refractory Rheumatoid Arthritis: All B/tsDMARD Classes Exhausted – An Uncommon Disease Subset with Distinct Inflammatory and Non-inflammatory Phenotypes
  • Abstract Number: 0719
    Polymyalgia Rheumatica Following SarsCOV-2 Vaccination: A Single Center Cohort Study
  • Abstract Number: 1934
    Pooled Safety Analysis from the VOLTAIRE Trials in Patients with Rheumatoid Arthritis, Crohn’s Disease, and Chronic Plaque Psoriasis
  • Abstract Number: 0002
    Population Pharmacokinetic and Pharmacodynamic Analyses of Obexelimab in Healthy Volunteers and in Patients with Rheumatoid Arthritis or IgG4-Related Diseases
  • Abstract Number: 1379
    Population Pharmacokinetic/Pharmacodynamic Modeling of Dazodalibep, a CD40L Antagonist, in Healthy Volunteers and Patients with Rheumatoid Arthritis and Sjogren’s Syndrome
  • Abstract Number: 0106
    Positive Antiphospholipid Antibodies Are Associated with a Higher Risk of Cerebral Microbleeds
  • Abstract Number: 2030
    Positive Psychosocial Factors May Protect Against Perceived Stress in a Multiethnic Cohort of People with SLE with and Without Trauma History
  • Abstract Number: 1828
    Positive Screening for Fibromyalgia or Depression on Validated MDHAQ Indices Is Seen in 56-71% of Rheumatoid Arthritis Patients with High DAS28 or CDAI, 40-47% with Moderate, 2-42% with Low, and 0-21% with DAS28 or CDAI Remission
  • Abstract Number: 0052
    Possible Involvement of TLR4 in the Pathogenesis of Primary Sjögren’s Syndrome Through Induction of the Expression of BAFF Receptor, BR3 in Peripheral Monocytes
  • Abstract Number: 0221
    Post-COVID-19 Autoimmune Serologies and Immunophenotypes
  • Abstract Number: 1187
    Post-hoc Analysis of Individual Questions from the Australian/Canadian Osteoarthritis Hand Index from a Randomized, Double-blind, Placebo-controlled Trial of Patients with Hand OA
  • Abstract Number: 0029
    Post-translationally Modified Fibrinogen Activated Macrophages Drive the Expression of Fibrotic Genes in Human Lung Fibroblasts
  • Abstract Number: 0373
    Potential Tear-Based Uveitis Biomarkers in Children with JIA: A Pilot Study
  • Abstract Number: 1387
    Power Doppler Musculoskeletal Abnormalities in Patients with Psoriasis at High Risk of Progression to Psoriatic Arthritis
  • Abstract Number: PP09
    Practicing Mindfulness to Improve Quality of Life
  • Abstract Number: 0089
    Pre-Clinical Characterization of MTX-101, a Novel Bispecific CD8 Treg Modulator with the Potential to Restore CD8 Treg Functions in Patients with Rheumatological Autoimmune Diseases
  • Abstract Number: 1935
    Pre-exposure Prophylaxis with Tixegvimab/cilgavimab Is Effective in Limiting the Risk and Severity of COVID-19 in Patients with Auto Immune or Inflammatory Diseases at Increased Risk of Severe COVID-19
  • Abstract Number: 2481
    Pre-pregnancy Gene Expression Signatures Among Women with Rheumatoid Arthritis May Represent Predictive Biomarkers for Subsequent Improvement or Worsening During Pregnancy
  • Abstract Number: 1492
    Pre-treatment Differentially Expressed Metagenes Characterize Systemic Lupus Patients Who Subsequently Achieve Clinical Response to Belimumab
  • Abstract Number: 0006
    Preclinical Characterization of a Novel anti-CD40 Antagonist Antibody-glucocorticoid Conjugate with Superior Preclinical Efficacy and Favorable Safety Profile
  • Abstract Number: 1132
    Preclinical Profiles of FZ007-119, a Highly Potent and Selective Tyk2 Inhibitor, for the Treatment of Immune Mediated Inflammatory Diseases
  • Abstract Number: 0175
    Predicting Cost-Related Medication Non-Adherence in US Adults with Chronic Arthritis: A Machine Learning Approach
  • Abstract Number: 2011
    Predicting Fractures in Patients with Isolated Lumbar Spine Osteoporosis Compared to Those with Isolated Hip Osteoporosis
  • Abstract Number: 1508
    Predicting in Virtual Patients the Efficacy of an Anti IFNa Mab in Cutaneous Lupus Erythematosus
  • Abstract Number: 2320
    Predicting Remission and Low Disease Activity Attainment in Patients with Systemic Lupus Erythematosus
  • Abstract Number: 2273
    Predicting SLE Disease Activity with Blood Biomarkers: A Step Towards Precision Medicine
  • Abstract Number: 1468
    Prediction of Cardiovascular Disease in Patients with Systemic Lupus Erythematosus Using a Machine Learning Algorithm for Time-to-Event Outcomes: Random Survival Forest
  • Abstract Number: 1390
    Prediction of Low Disease Activity in Patients with Ankylosing Spondylitis Treated with Secukinumab in Real World – Data from a German Observational Study
  • Abstract Number: 0489
    Prediction of Low Disease Activity in Patients with Psoriatic Arthritis Treated with Secukinumab in Real World – Data from a German Observational Study
  • Abstract Number: 0633
    Prediction of Progressive Fibrosing Interstitial Lung Disease in Systemic Sclerosis Patients: Insight from the CRDC Cohort Study
  • Abstract Number: 0644
    Prediction of Stable SSc-ILD Depends on Definition of ILD Progression
  • Abstract Number: 2053
    Predictive Factors Associated with Treatment Response in Chronic Nonbacterial Osteomyelitis
  • Abstract Number: 0843
    Predictive Validity of Data-driven Definitions for Active and Structural Lesions in the SI Joints Typical for Axial SpA: A 2-year Follow-up in the SPondyloArthritis Caught Early Cohort
  • Abstract Number: 2295
    Predictors of Adherence to Cervical Cancer Screening Guidelines Among Patients with Systemic Lupus Erythematosus
  • Abstract Number: 0222
    Predictors of Adverse Prognosis Following Hospitalization for COVID-19 Infection in Patients with Immune Mediated Inflammatory Diseases Treated with Rituximab
  • Abstract Number: 1463
    Predictors of Cognitive Impairment in Individuals with Systemic Lupus Erythematosus
  • Abstract Number: 0098
    Predictors of Mortality in Antiphospholipid Antibody Positive Patients: Prospective Results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository “Registry”
  • Abstract Number: 1107
    Predictors of Pegloticase Urate-lowering Response in the Presence and Absence of Methotrexate Co-therapy
  • Abstract Number: 0432
    Predictors of Use, Survival and Safety of Tofacitinib Monotherapy vs. in Combination with CsDMARDs in Daily Clinical Practice
  • Abstract Number: 0482
    Preference and Relative Sensitivity of Indicators Reporting Response Rate in Pharmaceutical Trials of Psoriasis and Psoriatic Arthritis
  • Abstract Number: 2278
    Pregnancy in Connective Tissue Diseases: A 30 Year Follow-up Study of 465 Pregnancies from a Spanish Monocentric Registry
  • Abstract Number: 2425
    Pregnancy Outcomes Among Patients with Vasculitis Using Administrative Claims Data
  • Abstract Number: 1968
    Pregnancy Outcomes in Idiopathic Inflammatory Myopathies: A Comparison to the General American Population
  • Abstract Number: 2482
    Preinflammatory Mesenchymal (PRIME) Cell Signature Genes Enrichment Predicts Treatment Response and Joint Prognosis in Rheumatoid Arthritis
  • Abstract Number: 1119
    Preliminary Descriptive Analysis of the RADIAL Cohort Study About the Prevalence and the Clinical Characteristics of Patients with CPPD in Daily Clinical Practice
  • Abstract Number: 0259
    Preliminary Experience with a Novel “Fix” for Deep Epitope and Transcriptional Phenotyping of Fragile Cells from Autoinflammatory Flares
  • Abstract Number: 1985
    Preliminary Results for the Total Knee Replacement Coaching Program for Patients Preparing to Undergo Total Knee Arthroplasty, a Pilot Randomized Trial
  • Abstract Number: 2604
    Premature Vascular Smooth Muscle Cells Senescence Driven by Interleukin-6-Mitochondrial STAT3-Mitofusin 2 Signaling in Takayasu’s Arteritis
  • Abstract Number: 0846
    Preosteoclast Plays a Pathogenic Role in Syndesmophyte Formation of Ankylosing Spondylitis Through the Secreted PDGFB – GRB2/ERK/RUNX2 Pathway
  • Abstract Number: 1506
    Prescribing Patterns in Lupus Nephritis: Analyzing Time from Proteinuria to Prescription of ACE/ARB
  • Abstract Number: 1186
    Presence of Erosions Is Not a Risk Factor for the Development of Knee OA in a Hand OA Population: The Framingham OA Study
  • Abstract Number: 0573
    Presence of Mediterranean Fever Gene Variants Provides Protection from the Development of Lupus Nephritis in Patients with Systemic Lupus Erythematosus
  • Abstract Number: 1478
    Presentation and Outcomes of Posterior Reversible Encephalopathy Syndrome in Systemic Lupus Erythematosus: A Multicenter Cohort and a Systematic Literature Review
  • Abstract Number: 0350
    Presentation, Management, and Outcomes of Systemic JIA-Associated Lung Disease: A Single Center Experience
  • Abstract Number: 1156
    Presentations and Outcomes of Idiopathic Inflammatory Myopathies in Hong Kong
  • Abstract Number: 0634
    Prevalence and Associations of Anaemia in Systemic Sclerosis Patients in a National Observational Cohort; Results from the Australian Scleroderma Cohort Study
  • Abstract Number: 2209
    Prevalence and Clinical Characteristics of Late Onset Axial Spondyloarthritis: Results from a Multicentre Nationwide Study
  • Abstract Number: 0305
    Prevalence and Clinical Significance of anti-Ro52 Antibodies in Antisynthetase Syndrome
  • Abstract Number: 2532
    Prevalence and Disease-Specific Factors Associated with Osteoporosis in Systemic Sclerosis: A Cross-Sectional Analysis of Two Large European Cohorts
  • Abstract Number: 1044
    Prevalence and Distribution of Sonographic Elementary Lesions in PsA – Results of 2 Cohorts
  • Abstract Number: 0707
    Prevalence and Distribution of Vascular Calcifications at CT Scan in Patients with Large Vessel Vasculitis and Patients with Lymphoma: A Matched Cross-sectional Study
  • Abstract Number: 1080
    Prevalence and Incidence of Paradoxical Side-effects of TNF-α Inhibitors: A Cross-sectional Study
  • Abstract Number: 0138
    Prevalence and Incidence of Sjögren’s Syndrome: A Systematic Literature Review
  • Abstract Number: 1923
    Prevalence and Patterns of Comorbidities in Different Rheumatic Diseases: A Study from Tertiary Healthcare Centre
  • Abstract Number: 0630
    Prevalence and Risk Factors for Systemic Sclerosis Digital Ischemic Complications in the Collaborative National Quality and Efficacy Registry
  • Abstract Number: 0647
    Prevalence and Risk Factors of Left Ventricular Diastolic Dysfunction in Systemic Sclerosis: Insights from New Echocardiographic Parameters
  • Abstract Number: 2130
    Prevalence and Risk Factors of Pneumocystis Jirovecii Colonization in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors and Tocilizumab
  • Abstract Number: 1942
    Prevalence and Screening Strategy for Latent Tuberculosis Infection in Patients with Rheumatic Immune-Mediated Diseases
  • Abstract Number: 0977
    Prevalence of Arthritis in the United States: National Estimates from a Population-based Study
  • Abstract Number: 0615
    Prevalence of Barrett’s Esophagus in Patients with Systemic Sclerosis
  • Abstract Number: 1469
    Prevalence of Cardiovascular Disease in a Populations Based Registry of Patients with Systemic Lupus Erythematosus
  • Abstract Number: 1238
    Prevalence of Celiac Disease Among Children and Adolescents with Systemic Lupus Erythematosus (SLE)
  • Abstract Number: 1411
    Prevalence of Early Axial Spondyloarthritis in the Be-GIANT Cohort Based on the ASAS Consensus Definition of Early Axial Spondyloarthritis
  • Abstract Number: 0475
    Prevalence of Endometriosis and Polycystic Ovarian Syndrome in Patients with Rheumatic Diseases in the United States
  • Abstract Number: 1275
    Prevalence of Frailty Among Individuals Living with Rheumatoid Arthritis: A Population-based Cohort Study
  • Abstract Number: 1472
    Prevalence of Hepatic Injury in Patients with Systemic Lupus Erythematosus: A 28-Year Single Center Experience
  • Abstract Number: 1091
    Prevalence of Loss to Follow up of Systemic Lupus Erythematosus Patients and Its Effect on Quality of Care
  • Abstract Number: 1832
    Prevalence of Musculoskeletal Manifestations in Post-acute COVID 19 Patients and Their Quality of Life at Kenyatta National Hospital
  • Abstract Number: 0395
    Prevalence of Objectively Measured Sleep Disturbance in Rheumatoid Arthritis (RA)
  • Abstract Number: 1487
    Prevalence of Objectively Measured Sleep Disturbance in Systemic Lupus Erythematosus (SLE)
  • Abstract Number: 2573
    Prevalence of Pulmonary Hypertension in a Cohort of Patients with Interstitial Pneumonia with Autoimmune Features and Its Effect on Lung Disease Progression and Mortality
  • Abstract Number: 0409
    Prevalence of Pulmonary Manifestations in Patients with Newly Diagnosed Rheumatoid Arthritis, Psoriatic Arthritis, and Peripheral Spondyloarthritis
  • Abstract Number: 0495
    Prevalence of Undiagnosed Inflammatory Bowel Disease in Patients with Spondyloarthritis: EISER Study
  • Abstract Number: 2553
    Prevalence, Determinants and Outcomes of Target Attainment in SLE Patients with Clinically Active Disease in a Large Multinational Prospective Lupus Cohort
  • Abstract Number: 1713
    Prevention of Arthritis Development by Mechanical Unloading Through Inhibition of CCL2 and YAP-mediated Inflammation in the Rat Adjuvant-induced Arthritis Model
  • Abstract Number: 1324
    Previous History of Serious Infection Is Associated with the Use of IL-6 Inhibitors in Rheumatoid Arthritis in Wales, UK
  • Abstract Number: 2248
    Primary Non-response in Psoriatic Arthritis Treated with Biologics and Targeted Synthetic Therapies in Daily Clinical Practice
  • Abstract Number: 0356
    PRINTO Provisional Enthesitis/Spondylitis-Related JIA Criteria: Performance in Youth Classified as Axial Disease in Juvenile Spondyloarthritis
  • Abstract Number: 1751
    Profiling of Anti-PAD IgG and IgA in Patients from the Head-to-head Adalimumab vs Abatacept Rheumatoid Arthritis AMPLE Trial and Matched Healthy Controls
  • Abstract Number: 1570
    Prognostic Assessment of the 2022 ACR/EULAR Classification Criteria for Takayasu Arteritis: A Multi-centre International Study
  • Abstract Number: 1173
    Prognostic Biomarkers and Radiological Features of Idiopathic Inflammatory Myopathy Associated Interstitial Lung Disease
  • Abstract Number: 0643
    Progression of Interstitial Lung Disease in Systemic Sclerosis Does Not Predict Further Progression
  • Abstract Number: 0288
    Proinflammatory Bioactive Lipid Mediators (BLM) Are Associated with Worse Anti-Oxidant Function of High Density Lipoproteins (HDL) in Patients with Idiopathic Inflammatory Myopathies (IIM)
  • Abstract Number: 0920
    Proinflammatory Neutrophils and NETs Mediate Skin and Kidney Inflammation During Lupus Flare in Asymptomatic Lupus-prone Mice Triggered by UVB
  • Abstract Number: 0203
    Projecting the Impact on Clinical Outcomes in ANCA-Associated Vasculitis of Delaying Retreatment with Rituximab for Vaccine Optimization
  • Abstract Number: 1285
    PROMIS Symptom Clusters Predict Disease Activity in the First 6 Months in Newly Diagnosed RA Patients Starting MTX Therapy: Data from the Canadian Early Arthritis Cohort
  • Abstract Number: 2264
    Proposal for Defining Moderate and Severe Activity States in Systemic Lupus Erythematosus. Impact on Flares and Other Outcomes
  • Abstract Number: 1682
    Prospective Evaluation of Anti-SSA/Ro Pregnancies Supports the Utility of High Titer Antibodies and Fetal Home Monitoring for the Detection of Fetal Atrioventricular Block
  • Abstract Number: 0578
    Prospective Observational Study of Microvascular C5b-9 Deposition in Non-lesional Skin in Systemic Lupus Erythematosus Patients and Its Correlation with Active Lupus Nephritis
  • Abstract Number: 1161
    Proteasome Inhibitor Repurposed for Dermatomyositis: Results of a Drug Repurposing Analysis Based on the Transcriptomic Signature of Patients’ Perifascicular Fibers Validated in Pre-clinical Models
  • Abstract Number: 2355
    Proteome-based Stratification of Therapeutic Target Population for MT-6194 in Systemic Sclerosis with Pulmonary Arterial Hypertension
  • Abstract Number: 0864
    Proteomic Analysis of Circulating Neutrophils from Osteoarthritis Patients Shows Metabolic Dysregulation That Is Associated with Decreased Physiologic Apoptosis
  • Abstract Number: 0023
    Proteomic Analysis of Plasma-derived Extracellular Vesicles Renders Glutathione Peroxidase 3 a Biomarker for Dermatomyositis
  • Abstract Number: 2439
    Proteomic and Genomic Profiling of Plasma Exosomes from Ankylosing Spondylitis Patients
  • Abstract Number: 1282
    Proteomic Signature in Peripheral Blood and Sputum in Rheumatoid Arthritis Patients with and Without Lung Involvement
  • Abstract Number: 2581
    Proteomic Signatures in Pre-Rheumatoid Arthritis Suggest Evolving Biological Pathways in Different Stages of Disease Development That May Inform Prediction and Prevention Strategies
  • Abstract Number: 0075
    Proteomic, Transcriptomic, and T-Cell Receptor (TCR) Profiling of Synovial Integrin-Expressing (InEx) T Cells in Axial Spondyloarthritis (axSpA)
  • Abstract Number: 2531
    Proton Pump Inhibitor Use Is Associated with Impaired Bone Mineral Density but Not Bone Microarchitecture in Patients with Inflammatory Rheumatic and Musculoskeletal Diseases Taking Glucocorticoids
  • Abstract Number: 1639
    PsA Patients of Diverse Ethnic and Racial Backgrounds Experience More Skin Psoriasis, Increased Pain, and Higher Rates of Radiographic Axial Disease
  • Abstract Number: 1640
    Psoriatic Disease Associated with Neuroconnectivity Alterations in the Default Mode Network
  • Abstract Number: 0393
    Pulmonary Involvement in Patients with Seropositive and ACPA Positive Rheumatoid Arthritis (RA-ILD) – Novel Screening Protocol for Early Detection of Pulmonary Involvement
  • Abstract Number: 0617
    Pulmonary Rehabilitation in Connective Tissue Disease-Related Interstitial Lung Diseases
  • Abstract Number: 1606
    Purinergic Signaling as a Potential Therapeutic Target for APS Thromboinflammation
  • Abstract Number: PP14
    Putting Lived Experience into Action: Flipping the Script on Living with a Chronic Disease
Jump to:  View All • a b c d e f g h i j k l m n o [p] q r s t u v w x y z
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology